Citable filing context
CRL's research view summarizes recent SEC filing context, starting with other from Sep 24, 2026.
| Filed | Item | Context |
|---|---|---|
| Sep 24, 2026 | other | Charles River Laboratories hosted an Investor Day to outline its Pathway to Purpose strategy and long-term financial targets. |
| Aug 5, 2026 | earnings | Charles River Laboratories reported Q2 2026 revenue of $1.00 billion and non-GAAP EPS of $3.02. |
| May 11, 2026 | other | Shareholders elected directors and approved the 2026 Long-Term Incentive Plan at the annual meeting. |
| Sep 24, 2026 | Guidance: non_gaap_eps | 11.15 to 11.45 |
| Sep 24, 2026 | Guidance: non_gaap_operating_margin | 21.00 to 21.30 |
| Sep 24, 2026 | Guidance: organic_revenue_growth | 0.00 to 1.00 |
| Aug 5, 2026 | mda_quarterly | Charles River Laboratories (CRL) is navigating a cautious demand environment, particularly within its Discovery and Safety Assessment (DSA) segment, where clients remain conservative despite a slight increase in backlog to $2.0 billion. To improve margins, the company is executing a $300 million annualized cost-savings program focused on workforce right-sizing, site consolidation, and global business services. Financial performance for the first half of 2026 reflects significant portfolio restructuring. Revenue declined slightly to $1.999 billion, pressured by the divestitures of the CDMO, Cell Solutions, and European Discovery Services businesses. While these sales resulted in substantial one-time charges—most notably a $181.7 million loss on the CDMO and Cell Solutions divestiture—they are intended to optimize the company’s long-term capital deployment. Operating income benefited from these actions, alongside a $38.5 million gain from a sale-leaseback transaction in Wilmington, Massachusetts. Strategic capital allocation remains focused on vertical integration, highlighted by the $507.3 million acquisition of a Cambodian non-human primate (NHP) supplier to secure supply chain stability. Liquidity remains sufficient, supported by a $2.0 billion revolving credit facility. The company continues to prioritize shareholder returns, repurchasing $300 million in common stock during the first half of 2026 under a $1 billion authorization. |
| May 7, 2026 | mda_quarterly | Charles River Laboratories is navigating a cautious spending environment, particularly within its Discovery and Safety Assessment (DSA) segment, where the backlog remains steady at $1.9 billion. To improve margins, the company is executing cost-saving initiatives targeting $300 million in cumulative annualized savings by the end of 2026 through workforce right-sizing and site optimization. First-quarter 2026 revenue increased 1.2% to $995.8 million, with growth in Microbial Solutions offsetting declines in Research Models and Services (RMS) large and small model product revenue. Despite an increase in operating income to $119.9 million—bolstered by a $38.5 million gain from a Wilmington asset sale-leaseback—the company reported a net loss of $14.8 million, primarily due to a $118 million pre-tax loss from the divestiture of its CDMO and Cell Solutions businesses. Strategic portfolio adjustments include the $507.3 million acquisition of a Cambodian non-human primate supplier and the $60 million acquisition of PathoQuest. Additionally, the company agreed to sell its European Discovery Services to IQVIA for $145 million. Liquidity is supported by a $2 billion credit facility, with $1.165 billion currently outstanding, and $800 million remaining in its $1 billion stock repurchase program. |
Source: SEC EDGAR filing text and events; period Sep 24, 2026; filed Sep 24, 2026.
CRL company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the research view.
A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.
A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.
A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.